Holger Auner

Has grant

Full Professor (Professeur ordinaire)

University of Lausanne

Switzerland

Research Interests

Explore related searches

Professors in Switzerland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Holger Auner is a Full Professor at the University of Lausanne, Switzerland. His research focuses on light-chain amyloidosis, acute myeloid leukemia, and multiple myeloma therapies, as highlighted in his recent publications. His work includes updating treatment recommendations and conducting clinical trials to improve patient outcomes in hematologic malignancies.

Recent Grants

Grant: Close

Identification and therapeutic targeting of proteostatic and metabolic vulnerabilities in multiple myeloma

Open Date: 2019-11-01

Close Date: 2024-11-01

Grant: Close

Targeting xxx to overcome proteasome inhibitor resistance in multiple myeloma

Open Date: 2019-07-01

Close Date: 2022-07-01

Grant: Close

Investigation of targetable vulnerabilities of leukaemia and lymphoma cells by next-generation sequencing and multi-omics based approaches

Open Date: 2019-02-01

Close Date: 2020-10-01

Grant: Close

Targeting proteostasis addiction in multiple myeloma to sensitize cells to proteasome inhibition

Open Date: 2017-08-01

Close Date: 2019-07-01

Grant: Close

Targeting Proteostasis Addiction in Haematopoietic Malignancies

Open Date: 2017-01-01

Close Date: 2017-10-01

Articles (10)

Year:

2025

Year:

2024

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (7)

Aristeidis Chaidos

Honorary Senior Clinical Lecturer

Imperial College London

UNITED KINGDOM

View details

Martin Kaiser

Professor of Haematology

The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust

UNITED KINGDOM

View details

Hang Quach

University of Melbourne

AUSTRALIA

View details

Andreas J. Flammer

SWITZERLAND

View details

Caroline Arber

Research Group Leader, Attending Physician, Associate Professor

Lausanne University Hospital

SWITZERLAND

View details

Alexandre Benechet

HEAD OF THE IN VIVO IMAGING FACILITY

SWITZERLAND

View details

Reuben Benjamin

Consultant Haematologist and Clinical Senior Lecturer

King's College Hospital

UNITED KINGDOM

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Holger Auner

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (10)

Updated recommendations for the treatment of light-chain amyloidosis from the Swiss Amyloidosis Network

Macrophage migration inhibitory factor blockade reprograms macrophages and disrupts prosurvival signaling in acute myeloid leukemia

Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial

MUKtwelve protocol: a phase II randomised, controlled, open, parallel group, multicentre trial of selinexor, cyclophosphamide and prednisolone (SCP) versus cyclophosphamide and prednisolone (CP) in patients with relapsed or refractory multiple myeloma

Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results

Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study.

Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.

Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone

Effect of age and frailty on the efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

Brd2/4 and Myc regulate alternative cell lineage programmes during early osteoclast differentiation in vitro.

Collaborators (7)

Aristeidis Chaidos

Martin Kaiser

Hang Quach

Andreas J. Flammer

Caroline Arber

Alexandre Benechet

Reuben Benjamin

Make your next move.